Human HLA-A*02:01&B2M&Glypican 3 (FVGEFFTDV) Tetramer Protein (MALS verified)

Catalog # HLG-H52E5



Synonym

HLA-A*02:01 & B2M & Glypican 3 (FVGEFFTDV)

Source

Human HLA-A*02:01&B2M&Glypican 3 (FVGEFFTDV) Tetramer Protein(HLG-H52E5) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Thr 305 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & FVGEFFTDV peptide (Accession # AAA59606.1 (HLA-A*02:01) & P61769 (B2M) & FVGEFFTDV).

Predicted N-terminus: Gly 25 & Phe

Molecular Characterization

Human HLA-A*02:01&B2M&Glypican 3 (FVGEFFTDV) Tetramer Protein is assembled by biotinylated monomer (HLG-H82E4) and streptavidin.

Biotinylated Human HLA-A*02:01&B2M&Glypican 3 (FVGEFFTDV) Complex Protein is produced by co-expression of HLA and B2M loaded with Glypican 3 peptide. Biotinylated Human HLA-A*02:01&B2M&Glypican 3 (FVGEFFTDV) Complex Protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (AvitagTM).

The protein has a calculated MW of 36.0 kDa and 13.8 kDa. The protein migrates as 42-45 kDa, 15 kDa and 14 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin

Less than 1.0 EU per μg by the LAL method / rFC method.

Purity

>90% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

Formulation

Lyophilized from $0.22~\mu m$ filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:


- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.

SDS-PAGE



Human HLA-A*02:01&B2M&Glypican 3 (FVGEFFTDV) Tetramer Protein on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

SEC-MALS



The purity of Human HLA-A*02:01&B2M&Glypican 3 (FVGEFFTDV) Tetramer Protein (Cat. No. HLG-H52E5) is more than 90% and the molecular weight of this protein is around 250-280 kDa verified by SEC-MALS.

Report

Bioactivity-ELISA




Human HLA-A*02:01&B2M&Glypican 3 (FVGEFFTDV) Tetramer Protein (MALS verified)

Catalog # HLG-H52E5



Human HLA-A*02:01&B2M&Glypican 3 (FVGEFFTDV) Tetramer Protein ELISA 0.1 μ g of Human HLA-A*02:01&B2M&Glypican 3 (FVGEFFTDV) Tetramer Protein per well



Immobilized Human HLA-A*02:01&B2M&Glypican 3 (FVGEFFTDV) Tetramer Protein (Cat. No. HLG-H52E5) at 1 μg/mL (100 μL/well) can bind Anti-B2M Antibody, Human IgG1 with a linear range of 0.1-1 ng/mL (Routinely tested).

Background

Glypican-3 (GPC3) is also known as Intestinal protein OCI-5, GTR2-2, MXR7, which belongs to the glypican family. Glypican 3 / GPC-3 is highly expressed in lung, liver and kidney. Glypican-3 inhibits the dipeptidyl peptidase activity of DPP4. Glypican-3 may be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs, and also may play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function. The Human HLA-A*0201 Glycipan 3 (FVGEFFTDV) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M and FVGEFFTDV peptide of the Glycipan 3.

